Arcturus Therapeutics (ARCT) Competitors $17.01 -0.29 (-1.68%) Closing price 04:00 PM EasternExtended Trading$17.02 +0.01 (+0.06%) As of 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock ARCT vs. ADPT, SRPT, ANIP, ARQT, VCEL, DYN, APGE, TWST, BEAM, and CDTXShould you be buying Arcturus Therapeutics stock or one of its competitors? The main competitors of Arcturus Therapeutics include Adaptive Biotechnologies (ADPT), Sarepta Therapeutics (SRPT), ANI Pharmaceuticals (ANIP), Arcutis Biotherapeutics (ARQT), Vericel (VCEL), Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Beam Therapeutics (BEAM), and Cidara Therapeutics (CDTX). These companies are all part of the "pharmaceutical products" industry. Arcturus Therapeutics vs. Its Competitors Adaptive Biotechnologies Sarepta Therapeutics ANI Pharmaceuticals Arcutis Biotherapeutics Vericel Dyne Therapeutics Apogee Therapeutics Twist Bioscience Beam Therapeutics Cidara Therapeutics Adaptive Biotechnologies (NASDAQ:ADPT) and Arcturus Therapeutics (NASDAQ:ARCT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment. Which has higher earnings & valuation, ADPT or ARCT? Arcturus Therapeutics has lower revenue, but higher earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Arcturus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAdaptive Biotechnologies$178.96M11.21-$159.49M-$0.82-16.07Arcturus Therapeutics$152.31M3.03-$80.94M-$2.23-7.63 Does the media prefer ADPT or ARCT? In the previous week, Adaptive Biotechnologies had 10 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 13 mentions for Adaptive Biotechnologies and 3 mentions for Arcturus Therapeutics. Adaptive Biotechnologies' average media sentiment score of 0.84 beat Arcturus Therapeutics' score of 0.51 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 7 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcturus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, ADPT or ARCT? Adaptive Biotechnologies has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.26, suggesting that its share price is 126% more volatile than the S&P 500. Is ADPT or ARCT more profitable? Arcturus Therapeutics has a net margin of -49.26% compared to Adaptive Biotechnologies' net margin of -59.07%. Arcturus Therapeutics' return on equity of -24.87% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets Adaptive Biotechnologies-59.07% -60.93% -23.03% Arcturus Therapeutics -49.26%-24.87%-17.75% Do institutionals & insiders believe in ADPT or ARCT? 99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 6.4% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Do analysts recommend ADPT or ARCT? Adaptive Biotechnologies currently has a consensus price target of $12.38, indicating a potential downside of 6.11%. Arcturus Therapeutics has a consensus price target of $50.57, indicating a potential upside of 197.30%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Adaptive Biotechnologies 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryArcturus Therapeutics beats Adaptive Biotechnologies on 10 of the 16 factors compared between the two stocks. Get Arcturus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ARCT and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ARCT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARCT vs. The Competition Export to ExcelMetricArcturus TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$461.99M$3.08B$5.76B$9.75BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-7.6320.9231.4526.39Price / Sales3.03355.43431.57159.28Price / CashN/A44.7137.7559.42Price / Book2.008.0410.566.59Net Income-$80.94M-$53.98M$3.27B$265.83M7 Day Performance-8.10%-0.89%0.60%0.18%1 Month Performance30.25%5.66%5.42%2.13%1 Year Performance-18.73%9.06%50.36%21.07% Arcturus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARCTArcturus Therapeutics2.683 of 5 stars$17.01-1.7%$50.57+197.3%-17.0%$461.99M$152.31M-7.63180ADPTAdaptive Biotechnologies2.5007 of 5 stars$12.67-2.5%$12.38-2.3%+195.1%$1.98B$178.96M-15.45790News CoverageSRPTSarepta Therapeutics4.5543 of 5 stars$18.06-10.7%$43.50+140.9%-86.8%$1.98B$1.90B-20.761,372ANIPANI Pharmaceuticals3.2411 of 5 stars$90.32-0.8%$84.75-6.2%+47.5%$1.97B$614.38M-117.30600Insider TradeARQTArcutis Biotherapeutics2.4777 of 5 stars$15.69-1.8%$19.80+26.2%+44.9%$1.92B$196.54M-20.92150Positive NewsVCELVericel2.3498 of 5 stars$35.79-3.3%$60.33+68.6%-31.7%$1.87B$237.22M298.27300News CoveragePositive NewsDYNDyne Therapeutics3.5676 of 5 stars$13.00+3.3%$34.07+162.1%-69.5%$1.79BN/A-3.37100Positive NewsAPGEApogee Therapeutics3.8646 of 5 stars$36.94-3.5%$99.00+168.0%-24.4%$1.76BN/A-8.9491News CoveragePositive NewsAnalyst ForecastTWSTTwist Bioscience3.8293 of 5 stars$27.39-4.2%$49.40+80.4%-39.8%$1.73B$312.97M-18.89990Positive NewsBEAMBeam Therapeutics2.2344 of 5 stars$16.44-1.2%$48.45+194.7%-35.3%$1.68B$60.27M-3.65510Positive NewsCDTXCidara Therapeutics3.6206 of 5 stars$64.13-3.4%$64.14+0.0%+402.2%$1.68B$1.27M-5.7690Positive News Related Companies and Tools Related Companies Adaptive Biotechnologies Alternatives Sarepta Therapeutics Alternatives ANI Pharmaceuticals Alternatives Arcutis Biotherapeutics Alternatives Vericel Alternatives Dyne Therapeutics Alternatives Apogee Therapeutics Alternatives Twist Bioscience Alternatives Beam Therapeutics Alternatives Cidara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ARCT) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredTrump’s betrayal exposedTrump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcturus Therapeutics Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcturus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access